Feeds:
Posts
Comments

Archive for the ‘BioTechnology – Venture Creation, Venture Capital’ Category

LIVE review – HubWeek – Harvard, MIT, MGH, Boston multiple locations, 10/10 – 10/15, 2017

Posted in BioTechnology - Venture Creation, Venture Capital on September 23, 2017| Leave a Comment »

LIVE HubWeek – Harvard, MIT, MGH, Boston multiple locations, 10/10 – 10/15, 2017

Reporter: Aviva Lev-Ari, PhD, RN

 

I attended several events on THU, October 12, 2017

DEEP DIVE: The AI Revolution in Medicine

9AM — 11:30AM Faneuil Hall

Panelists:

Jayashree Kalpathy-Cramer, PhD, co-director of the Quantitative Tumor Imaging at Martinos (QTIM) Lab at the A.A. Martinos Center for Biomedical Imaging at MGH

Tina Kapur, PhD, executive director of Image Guided Therapy, Department of Radiology, BWH

Katherine P. Andriole, PhD, FSIIM, director of Research Strategy and Operations, MGH and BWH Center for Clinical Data Science

Dina Katabi, PhD, Andrew & Erna Viterbi Professor of EE and CS at MIT, director of MIT Center for Wireless Networks and Mobile Computing

10:30 – 11:00AM: Generating data and other AI challenges

Highlights

  • Dina Katabi, PhD – presented 21st Century technologies under development at MIT
  • Katherine P. Andriole, PhD described innovations in EMR

Voices of Oncology Discovery – Presented by HMS Executive Education

Red Dome, 1:30-3PM

  • Thomas Lynch Jr., MD, Executive VP, CSO, BMS
  • Alice Shaw, MD, PhD, Paula O’Keeffe Endowed Chair of Thoracis Oncology, MGH, Associate Professor of Medicine, HMS
  • Arlene Sharpe, PhD, George Fabyan Prof. of Comparative Pathology, Co-Director Evergrande Center for Immunologic Disease, HMS
  • Linnea Olson, Artist, blogger, advocate and long-term cancer survivor
  • Stanley Y Shaw, MD, PhD, Associate Dean for Executive Education, HMS

Highlights

  • Success reported with targeted therapies, biomarkers facilitate Clinical Trial design provide benefits for translation to approval of therapies
  • Biomarkers enable to achieve enriched population in Clinical Trials
  • Genomics vs Tissue Agnostics – FDA approved a drug based on genomics ALONE
  • FDA – has a new directive requiring feedback from Patients
  • KRAS Mutation – no targeted therapy in existance yet
  • Targeted therapies are available for: EDFR, PD-L!, PD-L2, ALK
  • Price of Durg and Value to Patients: Impact on Big Pharma
  • Combination drug therapy is KING
  • Data analytics, Urgency for response to drugs, clinical trials have accelerated path to approval if no alternative on the market

VOICE of the Cancer survival patient:

  1. Don’t give up
  2. Patient must have a seat at the Table
  3. Cancer as chronic disease while a search for cure continues

The Personalized Cell Therapy Challenge: A Race against Time

Green Dome, 4:00PM – 5PM

Udit Batra, Dr. Shashi Murthy, David Williams, Bruce Levine, Goeff Hodge

 

Healthy Brain, Enlightened Brain

Faneuil Hall, 5;30PM – 7PM

Deepak Chopra, MD and Dr. Rudy Tanzi, Reverend Liz Walker

Highlights

  • Importance of Sleep

Health Buzz: Why How Much You Sleep Could Affect Your Risk for Alzheimer’s Disease

  • Importance od De-Stress Methods
  • Nutrition and Microbiome
  • Early detection of AD – 20 years before onset of symptomes

Book signing:

Super Brain: Unleashing the Explosive Power of Your Mind to Maximize Health, Happiness, and Spiritual Well-Being

by Rudolph E. Tanzi Ph.D. and Deepak Chopra

MGH- Institute for Brain Health

Jonathan Rosand, MD
Dr. Jonathan Rosand is a Co-Director and Co-Founder of the Mass General Institute for Brain Health, Professor of Neurology at Harvard, the J. P. Kistler Chair in Neurology, and Neurologist at Massachusetts General Hospital where he is Chief of the Division of Neurocritical Care and Emergency Neurology. A clinician-scientist with expertise in prevention of cerebrovascular diseases and preservation of brain function following stroke and brain injury, he brings the most advanced techniques of personalized medicine to his practice. In his laboratory within the Mass General Center for Human Genetic Research, Dr. Rosand directs a world-class research program in genetics that continues to discover new genes that influence susceptibility to and recovery from stroke.

Rudolph Tanzi, PhD
Dr. Rudy Tanzi is a Co-Director and Co-Founder of the Mass General Institute for Brain Health, Professor of Neurology and holder of the Joseph P. and Rose F. Kennedy Endowed Chair in Neurology and Mental Retardation at Harvard University, Vice-Chair of Neurology (Research) at MGH and Co-Chair of the Mass General Research Council. He received his Ph.D. in Neurobiology from Harvard University. The four new AD candidates discovered by the Alzheimer’s Genome Project, headed by Tanzi, were named as one of the ten top medical breakthroughs of 2008 by Time magazine. He has received the two highest awards in the field of AD research: The Metropolitan Life Award for Biomedical Research and the Potamkin Prize. Dr. Tanzi has co-authored over 450 research publications, and in 2012, co-authored the New York Times Best Selling book, “Super Brain”.

 

GO TO

https://hubweek.swoogo.com/tickets/begin?package_id=3184

Selection Price
The HUB Pass (FREE) $0.00
Designing Biology: New Paradigms for Collaboration
Oct 10, 2017, 10:30 AM – 12:15 PM		 $0.00
How the Hub is Steering the Digital Health Revolution
Oct 10, 2017, 4:30 PM – 7:00 PM		 $0.00
Total $0.00
Continue 
If you would like to register for more events, please select them below. If you have selected all the events that you would like to attend, please click “Continue” (You can always modify your schedule after you finish registering)

Choose your events:

Name Date & Time More Info
Leveraging Sustainable Design to Achieve Social Equity

Sold Out
 Tuesday, October 10, 2017, 8:00 AM – 10:00 AM
The Organ Generation

Sold Out
 Tuesday, October 10, 2017, 8:30 AM – 10:00 AM
Creating Connected Communities with Design Thinking–Ideation

Sold Out
 Tuesday, October 10, 2017, 9:00 AM – 12:00 PM
Boston Landing Development Presentation Tuesday, October 10, 2017, 10:00 AM – 11:00 AM
Maximize Innovation with Universal Design Tuesday, October 10, 2017, 10:00 AM – 12:00 PM
Mobile @Scale Tuesday, October 10, 2017, 10:00 AM – 5:00 PM
Designing Biology: New Paradigms for Collaboration Tuesday, October 10, 2017, 10:30 AM – 12:15 PM
Fitness Class at Athlete’s Park Tuesday, October 10, 2017, 11:00 AM – 12:00 PM
Public Skate at the Warrior Ice Arena Tuesday, October 10, 2017, 12:00 PM – 3:00 PM
Women in Science Luncheon Tuesday, October 10, 2017, 12:00 PM – 2:00 PM
Programming the Future of AI: Ethics, Governance, and Justice

Sold Out
 Tuesday, October 10, 2017, 12:00 PM – 1:00 PM
Salesforce Growth Camp Tuesday, October 10, 2017, 12:00 PM – 6:00 PM
Presentation Skills & Public Speaking Workshop

Sold Out
 Tuesday, October 10, 2017, 12:45 PM – 2:15 PM
The Human Face of AI

Sold Out
 Tuesday, October 10, 2017, 12:45 PM
Giza 3D: Visualizing the Pyramids

Sold Out
 Tuesday, October 10, 2017, 1:00 PM – 2:00 PM
Ancient DNA: Mediterranean Pathogens and Mobility Tuesday, October 10, 2017, 2:00 PM – 5:00 PM
Building a Startup in Boston

Sold Out
 Tuesday, October 10, 2017, 2:30 PM – 3:15 PM
The Art of Storytelling

Sold Out
 Tuesday, October 10, 2017, 2:45 PM – 4:15 PM
Innovation at Boston Health Care for the Homeless Tuesday, October 10, 2017, 3:00 PM – 4:30 PM
Breaking Into Biotech

Sold Out
 Tuesday, October 10, 2017, 3:30 PM – 5:00 PM
How AI Makes Us More Human

Sold Out
 Tuesday, October 10, 2017, 4:00 PM – 5:00 PM
“Walk A Mile” Poverty Simulation Tuesday, October 10, 2017, 4:00 PM – 6:30 PM
How the Hub is Steering the Digital Health Revolution Tuesday, October 10, 2017, 4:30 PM – 7:00 PM
How To Connect With Anyone Tuesday, October 10, 2017, 4:45 PM – 6:15 PM
The Future of Robotics

Sold Out
 Tuesday, October 10, 2017, 5:00 PM – 6:00 PM
Aging & Caregiving Digital Health Reverse Pitches Tuesday, October 10, 2017, 5:00 PM – 8:00 PM
The Neuroscience Behind Consumer Decision-Making Tuesday, October 10, 2017, 5:00 PM – 6:00 PM
Reducing & Managing Stress: Walking the Labyrinth Tuesday, October 10, 2017, 5:30 PM – 6:30 PM
Diversity in Business: How to Bring Meaningful Change Tuesday, October 10, 2017, 5:30 PM – 7:30 PM
Innovation in the Regional Food System Tuesday, October 10, 2017, 6:00 PM – 8:00 PM
When the Best Idea Fails Tuesday, October 10, 2017, 6:00 PM – 7:30 PM
Activating Purpose in the Workplace Tuesday, October 10, 2017, 6:00 PM – 8:00 PM
Venture Café Kendall Connect Tuesday, October 10, 2017, 6:00 PM – 7:30 PM
Open House at The Engine Tuesday, October 10, 2017, 6:00 PM
HUBweek Roxbury Innovation Showcase Tuesday, October 10, 2017, 6:00 PM – 9:00 PM
Hiring & Reskilling for the Future Tuesday, October 10, 2017, 6:30 PM – 8:30 PM
Create, Engage & Change: Urbano Project Open Studio Tuesday, October 10, 2017, 6:30 PM – 9:30 PM
Are You Truly Connected? Tuesday, October 10, 2017, 6:30 PM – 9:00 PM
The Changing Boston Designscape Tuesday, October 10, 2017, 6:30 PM – 8:30 PM
How To Be A Successful Networker Tuesday, October 10, 2017, 6:45 PM – 8:15 PM
The Science of 3D Knitting Tuesday, October 10, 2017, 7:45 PM
Finding Heaven Under Our Feet Tuesday, October 10, 2017, 8:00 PM – 9:45 PM
Behind The Scenes Of Successful Entrepreneurs Wednesday, October 11, 2017, 8:00 AM – 10:00 AM
Tour: Design Biennial Boston Wednesday, October 11, 2017, 8:30 AM – 9:30 AM
Engineering + Entrepreneurship: Innovation in Healthcare Wednesday, October 11, 2017, 9:00 AM – 3:00 PM
The Silk Road: Taking Breakthroughs Global Wednesday, October 11, 2017, 9:00 AM
Cancer Disparities + Diversity in Life Sciences Wednesday, October 11, 2017, 10:00 AM – 11:00 AM
MIT Public Art and Architecture Tour (Morning)

Sold Out
 Wednesday, October 11, 2017, 10:00 AM – 11:00 AM
War on Cancer 3.0 Wednesday, October 11, 2017, 11:00 AM – 12:00 PM
Kendall Square: Innovation Playground Wednesday, October 11, 2017, 12:00 PM
How to Attract Global Entrepreneurs to Boston Wednesday, October 11, 2017, 12:00 PM – 1:00 PM
AAUW Work Smart in Boston Salary Negotiation Workshop I Wednesday, October 11, 2017, 12:00 PM – 2:00 PM
Free Yoga & Meditation Class Wednesday, October 11, 2017, 12:15 PM – 2:00 PM
Creating Connected Communities with Design Thinking–Rapid Prototyping Wednesday, October 11, 2017, 1:00 PM – 4:00 PM
Bully Boy Distillery Tour Wednesday, October 11, 2017, 1:30 PM – 3:30 PM
Art of Talking Science Competition: Rise of the Machines Wednesday, October 11, 2017, 2:00 PM – 4:00 PM
MIT Public Art and Architecture Tour (Afternoon)

Sold Out
 Wednesday, October 11, 2017, 2:00 PM – 3:00 PM
The Harvard Yard Archaeology Project Wednesday, October 11, 2017, 2:30 PM – 3:30 PM
Inside the Brigham: Innovation in Action Wednesday, October 11, 2017, 3:00 PM – 6:00 PM
Marine Science Boston Harbor Cruise

Sold Out
 Wednesday, October 11, 2017, 3:00 PM – 5:00 PM
5th Annual BUILD Entrepreneur Games Wednesday, October 11, 2017, 3:00 PM – 7:30 PM
Healthcare Redesign Collaborative Wednesday, October 11, 2017, 3:30 PM – 6:00 PM
Ramp-Up E-commerce Conversions Wednesday, October 11, 2017, 3:45 PM – 5:45 PM
Healthcare and the Experience Economy Wednesday, October 11, 2017, 4:00 PM – 6:30 PM
Harvard Innovation Labs Startup Showcase and Stories Wednesday, October 11, 2017, 4:00 PM – 6:00 PM
Green Innovation Industry Night Wednesday, October 11, 2017, 4:00 PM – 8:00 PM
Decoding the Dynaymic Cyber Threat Landscape Wednesday, October 11, 2017, 4:00 PM – 6:30 PM
IoT for Good: Connected, Inclusive, Smart Cities

Sold Out
 Wednesday, October 11, 2017, 4:30 PM – 6:30 PM
Rare Rights. Common Cause. Wednesday, October 11, 2017, 4:45 PM
Dell PolicyHack Wednesday, October 11, 2017, 5:00 PM – 9:00 PM
The Female Entrepreneur’s Experience in Boston Wednesday, October 11, 2017, 5:00 PM – 7:00 PM
Love the Problem Showcase! Innovation That Solves Wednesday, October 11, 2017, 5:30 PM – 7:30 PM
AAUW Work Smart in Boston Salary Negotiation Workshop II Wednesday, October 11, 2017, 5:30 PM – 7:30 PM
Fall Café Night: District Hall’s 4th Birthday Party Wednesday, October 11, 2017, 5:30 PM – 9:00 PM
Geometry As Public Art: The Immigrant Experience Wednesday, October 11, 2017, 5:30 PM – 6:30 PM
Artificial Intelligence (and More) in Healthcare Wednesday, October 11, 2017, 5:30 PM – 7:30 PM
Celebration of Student Entrepreneurship in Boston Wednesday, October 11, 2017, 6:00 PM – 8:00 PM
Two Lenses: Communicating Science Wednesday, October 11, 2017, 6:00 PM – 8:00 PM
Innovation, the New Foundation of Urban Living Wednesday, October 11, 2017, 6:00 PM – 7:30 PM
Twilight: Exploring the Unconscious Mind Wednesday, October 11, 2017, 6:00 PM – 7:30 PM
The City Talks: STEAM Wednesday, October 11, 2017, 6:00 PM – 7:00 PM
Fact/Fiction: Driving Truth into Policy Debates Wednesday, October 11, 2017, 6:00 PM – 7:30 PM
Civic Series presents: Breaking Through Gridlock Wednesday, October 11, 2017, 6:00 PM – 8:30 PM
Runnin’: A circle of friends. An American epidemic. Wednesday, October 11, 2017, 6:30 PM – 8:00 PM
GlobeDocs: Opening Night Film–Bending the Arc Wednesday, October 11, 2017, 7:00 PM – 9:00 PM
GlobeDocs: Opening Night Film–Bending the Arc + Reception Wednesday, October 11, 2017, 7:00 PM – 11:00 PM
Environmental Film Festival: Happening – A Clean Energy Revolution Wednesday, October 11, 2017, 7:00 PM – 9:00 PM
The City Talks: Art and Medicine Wednesday, October 11, 2017, 7:30 PM – 8:30 PM
Innovation Women Pop-up (Thursday) Thursday, October 12, 2017, 8:00 AM
Deep Dive: The A.I. Revolution in Medicine Thursday, October 12, 2017, 9:00 AM – 12:00 PM
What it Means to be Part of a Movement Thursday, October 12, 2017, 11:00 AM – 12:00 PM
Exploration Phase I (Thursday) Thursday, October 12, 2017, 12:00 PM – 1:00 PM
Swiss-Made: Fulldome Immersive I (Thursday) Thursday, October 12, 2017, 1:00 PM – 1:30 PM
Swiss-Made: Fulldome Immersive II (Thursday) Thursday, October 12, 2017, 1:30 PM – 2:00 PM
Made in USA: Fulldome Immersive I (Thursday) Thursday, October 12, 2017, 2:00 PM – 2:30 PM
Deep Dive: Voices of Oncology Thursday, October 12, 2017, 2:00 PM – 3:30 PM
Do We Trust Our Digital Economy? Thursday, October 12, 2017, 2:30 PM – 3:30 PM
Abstract Superconscious (Thursday) Thursday, October 12, 2017, 2:30 PM
SAT FEST 2017 (Thursday) Thursday, October 12, 2017, 3:00 PM – 3:45 PM
Uncharted Domain (Thursday) Thursday, October 12, 2017, 3:00 PM
Linked Threats: Climate Change and Social Inequality Thursday, October 12, 2017, 3:35 PM – 4:15 PM
Made in USA: Fulldome Immersive II (Thursday) Thursday, October 12, 2017, 3:45 PM – 4:45 PM
Social Justice and the New Food Activism Thursday, October 12, 2017, 4:00 PM – 5:30 PM
Investing in American Jobs Thursday, October 12, 2017, 4:15 PM – 5:00 PM
Fullscale Dome-ination (Thursday) Thursday, October 12, 2017, 4:30 PM – 5:00 PM
Future Forum: Thursday Night Session Thursday, October 12, 2017, 5:00 PM – 7:00 PM
Swiss-Made: Fulldome Immersive III (Thursday) Thursday, October 12, 2017, 5:00 PM – 5:30 PM
Swiss-Made: Fulldome Immersive IV (Thursday) Thursday, October 12, 2017, 5:30 PM – 6:00 PM
MIT IDE Inclusive Innovation Challenge Celebration Thursday, October 12, 2017, 6:00 PM – 7:30 PM
Immersion Artists Talk Series Thursday, October 12, 2017, 6:30 PM – 8:30 PM
LIVE Silent Disco Thursday, October 12, 2017, 7:00 PM – 10:00 PM
Exploration Phase II (Thursday) Thursday, October 12, 2017, 7:00 PM – 8:00 PM
Wasted! The Story of Food Waste Thursday, October 12, 2017, 7:00 PM – 9:00 PM
GlobeDocs: Unrest Thursday, October 12, 2017, 7:30 PM – 9:30 PM
Live: Disorder 3D–Digital Choreography (Thursday) Thursday, October 12, 2017, 8:00 PM – 8:30 PM
Live: Disorder 3D–Digital Choreography (Friday) Thursday, October 12, 2017, 8:45 PM – 9:15 PM
Live: Disorder 3D–Digital Choreography (Saturday) Thursday, October 12, 2017, 9:30 PM – 10:00 PM
Innovation Women Pop-up (Friday) Friday, October 13, 2017, 8:00 AM
Deep Dive: Climate Change Friday, October 13, 2017, 9:00 AM – 12:00 PM
Swiss-Made: Fulldome Immersive I (Friday) Friday, October 13, 2017, 9:00 AM – 9:30 AM
Disrupting Poaching Networks Before They Kill Friday, October 13, 2017, 9:15 AM – 10:00 AM
Swiss-Made: Fulldome Immersive II (Friday) Friday, October 13, 2017, 9:30 AM – 10:00 AM
Made in USA: Fulldome Immersive II (Friday) Friday, October 13, 2017, 10:00 AM – 10:45 AM
Around Us. On Us. Within Us. Friday, October 13, 2017, 10:30 AM – 11:15 AM
Abstract Superconscious (Friday) Friday, October 13, 2017, 10:45 AM
Housing the Workforce:Typology Technology & Tectonics Friday, October 13, 2017, 11:05 AM – 11:55 AM
Initiative: The Women Behind Digital Health Friday, October 13, 2017, 12:00 PM – 1:15 PM
Exploration Phase I (Friday) Friday, October 13, 2017, 12:00 PM – 1:00 PM
Deep Dive: Innovations in Opioid Treatment and Recovery Friday, October 13, 2017, 1:00 PM – 4:00 PM
Swiss-Made: Fulldome Immersive III (Friday) Friday, October 13, 2017, 1:00 PM – 1:30 PM
Swiss-Made: Fulldome Immersive IV (Friday) Friday, October 13, 2017, 1:30 PM – 2:00 PM
Made in USA: Fulldome Immersive I (Friday) Friday, October 13, 2017, 2:00 PM – 2:30 PM
Planetary Explorations (Friday) Friday, October 13, 2017, 2:30 PM – 3:00 PM
Leading for Creativity Friday, October 13, 2017, 3:50 PM – 4:30 PM
Stories Under the Stars (Friday) Friday, October 13, 2017, 4:00 PM
Friday Night Session: Saving As Many Lives As Penicillin

Sold Out
 Friday, October 13, 2017, 5:00 PM – 7:00 PM
The Swiss Touch: Exploring Digital Utopia Friday, October 13, 2017, 5:00 PM – 7:00 PM
Beantown Throwdown Friday, October 13, 2017, 5:30 PM – 8:00 PM
Askwith Forum – Changes in Mind Friday, October 13, 2017, 5:30 PM – 7:00 PM
Coffee & Chocolate: Climate Change, Sustainability, and Gender Equity Friday, October 13, 2017, 6:00 PM – 8:30 PM
The Room Where It Happens: On the Agency of Interior Spaces (Keynote) Friday, October 13, 2017, 6:00 PM – 7:30 PM
Environmental Film Festival: Chasing Coral Friday, October 13, 2017, 6:30 PM – 9:00 PM
Unchained Brain Friday, October 13, 2017, 6:30 PM – 7:45 PM
Exploration Phase II (Friday) Friday, October 13, 2017, 7:00 PM – 8:00 PM
GlobeDocs: Human Flow Friday, October 13, 2017, 7:30 PM – 9:30 PM
On Point Live Friday, October 13, 2017, 7:30 PM – 9:00 PM
The Cypher Friday, October 13, 2017, 8:00 PM – 10:30 PM
SAT FEST 2017 (Friday) Friday, October 13, 2017, 8:45 PM – 9:30 PM
Fullscale Dome-ination (Friday) Friday, October 13, 2017, 9:30 PM – 10:00 PM
Planetary Explorations (Friday Night) Friday, October 13, 2017, 10:00 PM – 10:30 PM
Cosmic Meditation (Saturday) Saturday, October 14, 2017, 8:15 AM
The Room Where It Happens: On the Agency of Interior Spaces (Symposium) Saturday, October 14, 2017, 9:00 AM – 5:00 PM
Made in USA: Fulldome Immersive II (Saturday) Saturday, October 14, 2017, 9:30 AM – 10:15 AM
De-Stress Boston Saturday, October 14, 2017, 10:00 AM – 12:00 PM
Demo Day: Showcase Floor Saturday, October 14, 2017, 10:00 AM
Demo Day: Intro to Startups and Entrepreneurship in Boston Saturday, October 14, 2017, 10:00 AM – 10:50 AM
Intergalactic Yoga (Saturday) Saturday, October 14, 2017, 10:15 AM
Demo Day: Growing a Startup in Boston: Challenges and Advantages Saturday, October 14, 2017, 11:00 AM – 11:50 AM
Uncharted Domain (Saturday) Saturday, October 14, 2017, 11:30 AM
Demo Day: How to be an Ally in the Workplace Saturday, October 14, 2017, 12:00 PM – 12:50 PM
Exploration Phase I (Saturday) Saturday, October 14, 2017, 12:00 PM – 1:00 PM
GlobeDocs: Circle Up/Lenox Street Saturday, October 14, 2017, 12:00 PM – 2:00 PM
Demo Day: Founders Talking About Failure Saturday, October 14, 2017, 1:00 PM – 1:50 PM
Swiss-Made: Fulldome Immersive I (Saturday) Saturday, October 14, 2017, 1:00 PM – 1:30 PM
Swiss-Made: Fulldome Immersive II (Saturday) Saturday, October 14, 2017, 1:30 PM – 2:00 PM
Abstract Superconscious (Saturday) Saturday, October 14, 2017, 2:00 PM
Demo Day: An Introduction to Funding Types Saturday, October 14, 2017, 2:00 PM – 2:50 PM
Swiss-Made: Fulldome Immersive III (Saturday) Saturday, October 14, 2017, 2:30 PM – 3:00 PM
GlobeDocs: Anatomy of a Male Ballet Dancer Saturday, October 14, 2017, 2:30 PM – 4:30 PM
Swiss-Made: Fulldome Immersive IV (Saturday) Saturday, October 14, 2017, 3:00 PM – 3:30 PM
Making a Live Storytelling Show for a Planetarium Saturday, October 14, 2017, 3:45 PM
Stories Under the Stars (Saturday) Saturday, October 14, 2017, 4:30 PM
GlobeDocs: Gladesmen – The Last of the Sawgrass Cowboys Saturday, October 14, 2017, 5:00 PM – 7:00 PM
Krip-Hop Nation: The Crossroads Experience Saturday, October 14, 2017, 5:00 PM – 6:00 PM
Made in USA: Fulldome Immersive I (Saturday) Saturday, October 14, 2017, 5:15 PM – 5:45 PM
SAT FEST 2017 (Saturday) Saturday, October 14, 2017, 5:45 PM – 6:30 PM
Demo Day: Finale Saturday, October 14, 2017, 6:00 PM – 8:00 PM
Fullscale Dome-ination (Saturday) Saturday, October 14, 2017, 6:30 PM – 7:00 PM
Exploration Phase II (Saturday) Saturday, October 14, 2017, 7:00 PM – 8:00 PM
WGBH: First Look: Bill Nye – Science Guy Saturday, October 14, 2017, 7:00 PM – 9:00 PM
GlobeDocs: Jaha’s Promise Saturday, October 14, 2017, 7:30 PM – 9:30 PM
Pico Picante Saturday, October 14, 2017, 8:00 PM – 10:30 PM
Modulate Live–Dance Party Saturday, October 14, 2017, 9:15 PM – 10:45 PM
Intergalactic Yoga (Sunday) Sunday, October 15, 2017, 9:00 AM
Stories Under the Stars (Sunday) Sunday, October 15, 2017, 10:15 AM
Cosmic Meditation (Sunday) Sunday, October 15, 2017, 10:45 AM
Robot Block Party Sunday, October 15, 2017, 11:00 AM
GlobeDocs: Shorts Program–Changing Perspective Sunday, October 15, 2017, 11:30 AM – 1:30 PM
Green Up New England Challenge Sunday, October 15, 2017, 11:45 AM – 12:45 PM
Exploration Phase I (Sunday) Sunday, October 15, 2017, 12:00 PM – 1:00 PM
Butterfly Effect: A Study in Prototyping, Art and Sustainability Sunday, October 15, 2017, 12:00 PM – 1:00 PM
Design Museum: Digitally-Enabled Creativity Sunday, October 15, 2017, 1:00 PM – 2:15 PM
Abstract Superconscious (Sunday) Sunday, October 15, 2017, 1:00 PM
A New Wave of Public Art in the Boston Area Sunday, October 15, 2017, 1:00 PM – 2:15 PM
Made in USA: Fulldome Immersive I (Sunday) Sunday, October 15, 2017, 1:30 PM – 2:00 PM
Planetary Explorations (Saturday) Sunday, October 15, 2017, 2:00 PM – 2:30 PM
GlobeDocs: Hondros Sunday, October 15, 2017, 2:00 PM – 4:00 PM
Designing for Climate Change Sunday, October 15, 2017, 2:20 PM – 3:00 PM
Fullscale Dome-ination (Sunday) Sunday, October 15, 2017, 2:30 PM – 3:00 PM
Creative Placemaking – A View on Tactical Urbanism Sunday, October 15, 2017, 3:30 PM – 4:30 PM
Swiss-Made: Fulldome Immersive III (Sunday) Sunday, October 15, 2017, 3:30 PM – 4:00 PM
GlobeDocs: Quest Sunday, October 15, 2017, 4:30 PM – 6:30 PM
GlobeDocs: I Am Evidence Sunday, October 15, 2017, 4:30 PM – 6:30 PM
GlobeDocs: Closing Night Film–A Fine Line Sunday, October 15, 2017, 7:00 PM – 9:00 PM
WGBH: First Look: Frontline: Putin’s Revenge Sunday, October 15, 2017, 7:00 PM – 9:00 PM
GlobeDocs: Closing Night Film–A Fine Line + Reception Sunday, October 15, 2017, 7:00 PM – 11:00 PM
Immersion Party 3-Pack

 

 

 

Read Full Post »

Success of the life sciences industry in Massachusetts: Governor Charlie Baker – A new 5 year, $500 million investment

Posted in BioTechnology - Venture Creation, Venture Capital on June 19, 2017| Leave a Comment »

Success of the life sciences industry in Massachusetts: Governor Charlie Baker – A new 5 year, $500 million investment

Reporter: Aviva Lev-Ari, PhD, RN

 

We are thrilled to share this exciting news with you. Earlier today, Governor Charlie Baker announced he will be filing legislation to establish the next phase of the life sciences initiative with a new 5 year, $500 million investment. As the original 10-year, $1 billion program expires next year, this action is critical to the continued success of the life sciences industry in Massachusetts, and to patients around the world who continue to seek new treatments and cures they need and deserve.

As noted by the Governor’s office, the focus of this next phase of the life science initiative will include strengthening investments in human capital to fortify the state’s skilled workforce pipeline, expanding opportunities for companies to access both private investment capital and dynamic public infrastructure resources, developing new scientific innovations that deliver higher outcome, affordable therapies to patients, and leading the convergence revolution in digital health, biopharma, medical devices and engineering.

Over the last nine years the life science initiative and the Massachusetts Life Sciences Center has cemented Massachusetts as the life sciences leader nationally and across the world. In Cambridge and Boston we have the best, most dense biotech cluster in the world. In Worcester, we have a cluster which can stand on its own as one of the biggest in the country. And in the northern and southern parts of the state, jobs in the life sciences are growing faster than anywhere else in the state. With a $147,000 average salary, $9 billion in total payroll, and an expected 11,600 new jobs over the next five years, the life sciences is a huge economic engine for this state. With today’s announcement, we know that companies will continue to come and expand in Massachusetts for years to come and make our economy grow. 

Most importantly, the continuation of the life sciences initiative ensures that patients across the world will continue to receive the breakthrough cures and treatments that are being developed every day in Massachusetts. 

Today’s an exciting day for Massachusetts. We’re thrilled to be part of it.

– Bob Coughlin

 

SOURCE
From: MassBio <communications@massbio.ccsend.com> on behalf of MassBio <robert.coughlin@massbio.org>

Reply-To: <communications@massbio.org>

Date: Monday, June 19, 2017 at 1:06 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Breaking News: Gov. Baker Announces Next Phase of Life Sciences Initiative

Read Full Post »

VC Investment in BioTech MegaHubs and Top R&D Spenders among Big Pharma

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Drug Development Process, FDA Regulatory Affairs, Venture Capital on April 24, 2017| Leave a Comment »

VC Investment in BioTech MegaHubs and Top R&D Spenders among Big Pharma

Reporter: Aviva Lev-Ari, PhD, RN

UPDATED on 4/26/2017

The top 10 pharma R&D budgets in 2016

The Top 10 Pharma R&D Budgets in 2016

http://www.fiercebiotech.com/special-report/top-10-pharma-r-d-budgets-2016?utm_medium=nl&utm_source=internal&mrkid=993697&mkt_tok=eyJpIjoiT1RSbE9ESTRNR1pqWTJFNCIsInQiOiJFcUx4MFhxSFVGbVZhUkRGdUdRMTJMUGxFSEkrR0VTMEdXbjRvZkxmdXM4em4wRkg5QXZIOWJJWTgwNHR1a1dVbTRIUFwvNWRIXC9ZTkF5dHlpUUZ4bG1lS2c2NkszQk9oeGtRczhLcnYyalRSZEFjOEl6U3dUY2VaakxUbDdkNGNwIn0%3D

 

 

 

Table SOURCE: Thomson Reuters abd ENDPOINTS

According to both sources:

  • $3.5 billion for Silicon Valley plus the Bay Area and
  • $2.8 billion for New England.

Broken down by city, $6.1 billion went to

  • Boston ($2.7 billion),
  • San Jose ($2.5 billion) and
  • San Francisco/Berkeley ($1 billion).
  • San Diego ($725 million),
  • New York ($454 million) and
  • the Great Lakes area ($412 million)

SOURCE

Where the money is: Biotech’s megahubs command VC’s billions by john carroll, June 30, 2016 10:41 AM EDT, Updated: November 17, 2016 07:32 PM

https://endpts.com/where-the-money-is-biotechs-megahubs-command-vcs-billions/

The top 15 spenders in the global drug R&D business: 2017

by john carroll, 

April 24, 2017 05:22 AM EDT, Updated: 05:27 AM

The top five in the business saw their collective spending jump by more than $5 billion, from 2015 to 2016, based on the annual numbers filed largely — though not entirely — with the SEC and gathered by Endpoints News. Two of those companies,

  • Roche and the new number 2, a hard charging
  • Merck, accounted for the lion’s share of the increase. (To be sure, some onetime non-R&D spending, such as Merck’s patent settlement with Bristol-Myers on Keytruda, figured in. But so did bread and butter spending.)
  • Gilead also saw a significant increase in research costs, with
  • Eli Lilly — now off course following two bad setbacks for solanezumab and baricitinib — and the ever aggressive
  • Celgene joining the action as they pressed the accelerator on new drug programs.

Curiously, the added spending coincided with a bad drop in new drug approvals in 2016. But they don’t correlate, and we’ve already seen that turnaround under way as regulators get busy with a brand new year — and soon a brand new FDA commissioner.

SOURCE

https://endpts.com/special/top-research-budgets-in-pharma-and-biotech/

Read Full Post »

Chan-Zuckerberg (CZ) Biohub Selects Researchers to Receive $50 Million to Fight Disease & Consortium aimed at Immunotherapy Research

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Foundations for supporting Science and Education on February 13, 2017| Leave a Comment »

Chan-Zuckerberg (CZ) Biohub Selects Researchers to Receive $50 Million to Fight Disease & consortium aimed at immunotherapy research

 

Reporter: Aviva Lev-Ari, PhD, RN

 

 

02/10/2017 – 4:33pm
by Ryan Bushey
Digital Editor

 

Selecting the Candidates

It wasn’t easy to narrow down the applicant pool, according to Quake.

“Over 750 people submitted a three-page application proposing risky but innovative ideas. In return, we’d provide them with the funding to work on their ideas in an unrestricted capacity,” said Quake regarding the application process.

A panel comprised of 60 prominent engineers and scientists sifted through the applications that came from the three universities. Submissions came from a diverse array of departments, including computer science, engineering and mathematics before settling on the final 47 participants.

“It’s a phenomenal gathering of talent working on issues like using computer science to help understand human health through the use of wearables,” added Quake.

One notable member of this program is Jure Leskovec, Ph.D., who is a computer scientist at Stanford and the chief scientist at Pinterest. His work at the biohub will focus on using data to help biologists comprehend the interactions between the genes and proteins exposed to drugs or disease, according to Nature.

Other investigators include Ada Poon, Ph.D., hailing from Stanford who is studying new techniques for miniaturing bioelectronics devices, and Markita Landry, Ph.D., who is working on nanosensor technology and near infrared imaging platforms designed to visualize neurotransmitters in the brain.

The CZ Biohub will institute policies that enable quick dissemination of research papers through pre-print servers. This will help inform other researchers of their work and expedite the discovery process.

Next Steps

Investigators will gain a five-year appointment and up to $1.5 million in funding to kick start their research projects.

There are other research institutes forming in Silicon Valley, but with slightly different approaches. Sean Parker, the entrepreneur behind notorious music-sharing service Napster, launched a consortium aimed at immunotherapy research as well as a separate operation geared towards allergy research.

However, Quake said the Biohub concept appeals to a lot of researchers.

“There’s only a small number of faculty positions available each year and not everyone wants to teach, so we want the Biohub to be an alternate career path for researchers who love science,” he said.

http://www.rdmag.com/article/2017/02/chan-zuckerberg-biohub-selects-researchers-receive-50-million-fight-disease?et_cid=5825577&et_rid=461755519&type=cta&et_cid=5825577&et_rid=461755519&linkid=content

 

RELATED READS

Zuckerberg, Chan Pledge $3B to End Disease

Genomic Sequencing Illuminates Recent Shigella Outbreaks in California

Understanding the Full Scope of Renovation

Genome Engineering Paves Way for Sickle Cell Cure

Read Full Post »

Independent Public Relations Professionals with extensive experience in the biotechnology/drug development sector – Please Contact Me

Posted in BioTechnology - Venture Creation, Venture Capital, Seeking Talent on February 3, 2017| Leave a Comment »

Independent Public Relations Professionals with extensive experience in the biotechnology/drug development sector – Please Contact Me

Reporter: Aviva Lev-Ari, PhD, RN

We are seeking an independent public relations professional with extensive experience in the biotechnology/drug development sector to assist on a freelance basis to

  • promote an on line resource in drug development and personalized medicine in the global oncology sector. 

Responsibilities include working with agencies such as PR Newswire to distribute press releases prepared by us in house, and managing our proprietary mailing list and our social media accounts. 

Please, provide a detailed resume with contact information to knowledgebase@newmedinc.com.

 

Read Full Post »

Institutional Capital Raised by Female Founders in 2016 – A Global Perspective vs the US Economy: Globally 1,272 in the United States 600

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Institutional Capital Raised by Female Founders, Venture Capital on February 1, 2017| Leave a Comment »

Institutional Capital Raised by Female Founders in 2016 – A Global Perspective vs the US Economy: Globally 1,272 in the United States 600

Reporter: Aviva Lev-Ari, PhD, RN

2016 REVIEW OF FEMALE FOUNDERS RAISING INSTITUTIONAL CAPITAL

February 1, 2017
by Claire Burke and Kate Dwyer

– See more at:

http://femalefoundersfund.com/2016-review-of-female-founders-raising-institutional-capital/#sthash.Pcuj7rVB.dpuf

 

The Data Reflects Several Key Trends
Key Takeaways

Raising a Series A led by an institutional VC remains difficult, but female founders in NYC continued to be the most successful (compared to those in other cities) in 2016.
At 17%, the percentage of total A rounds led by female CEOs in 2016 represents the highest total percentage since Female Founders Fund started tracking the data in 2013.
In addition, New York saw a record number of Series B and C rounds led by female founders in 2016.
Female Founders Fund remains the most active institutional VC firm investing in early-stage female-led companies.
Funds that have traditionally been uninterested in e-commerce have renewed interest in the e-commerce sector following the Dollar Shave Club and Jet.com acquisitions by large strategic investors.

2016 Series A Rounds — NYC — Female CEO
Rockets of Awesome — $12.5 million — December — Rachel Blumenthal
Ellevest — $9.0 million — September — Sallie Krawcheck
CoheroHealth — $9.0 million — November — Melissa Manice
Away — $8.5 million — September — Steph Korey
Primary– $8.0 million — June — Galyn Bernard
goTenna — $7.5 million — March — Daniela Perdomo
LOLA — $7.0 million — December — Alex Friedman and Jordana Kier
Uncharted Play — $7.0 million — September — Jessica Matthews
Thrive Global — $7.0 million — August — Arianna Huffington
Everplans — $6.4 million — June — Abby Schneiderman
pymetrics — $6.1 million — February — Frida Polli
Sakara Life — $4.8 million — January — Whitney Tingle, Danielle DuBoise
Shoppable — $3.5 million — August — Heather Marie
MMLaFleur — Sarah LaFleur

2016 Series A Rounds — Bay Area — Female CEO

Cortexyme — $15.0 million — January — Casey Lynch
FOVE — $11.0 million — March — Yuka Kojima
Front — $10.0 million — May — Mathilde Collin
REBBL — $10.0 million — December — Sheryl O’Loughlin
Nima — $9.2 million — May — Shireen Yates
Rocksbox — $8.7 million — March — Meaghan Rose
LaunchDarkly — $8.7 million — December — Edith Harbaugh
Modsy — $8.0 million — February — Shanna Tellerman
ThirdLove — $8.0 million — February — Heidi Zak
Node — $7.5 million — June — Falon Fatemi
Shippo — $7.0 million — September — Laura Behrens Wu
Mobilize — $6.5 million — September — Sharon Savariego
Neurotrack — $6.5 million — January — Elli Kaplan
Sourcery — $5.0 million — September — Na’ama Moran
Luka — $4.4 million — April — Eugenia Kuyda
SupportPay — $4.1 million — December — Sheri Atwood
Zybooks — $4.0 million — February — Smita Bakshi
Schoola — $3.6 million — May — Stacey Boyd

– See more at:

http://femalefoundersfund.com/2016-review-of-female-founders-raising-institutional-capital/#sthash.Pcuj7rVB.dpuf

 

 

Series A Rounds in 2016

Our 2016 analysis began with an overall review of Series A rounds globally, nationally and regionally.

2017 Research Graph 1

Series A Rounds Raised Globally, Nationally and Regionally in 2016

Series A Rounds in 2016:

 

 

 

2016 Series A Rounds in 2016:

Globally: 1,272
United States: 600
Bay Area: 187
NYC: 84
Boston: 31
Los Angeles: 38
Seattle: 26
Austin: 7
Washington D.C.: 17

2015 Series A Rounds in 2015:

Globally: 1,164

United States: 664

Bay Area: 205

NYC: 96

Boston: 50

Los Angeles: 40

Seattle: 25

Austin: 22

Washington D.C.: 17

– See more at:

http://femalefoundersfund.com/2016-review-of-female-founders-raising-institutional-capital/#sthash.Pcuj7rVB.dpuf

The total number of Series A rounds in the U.S. decreased by 10% in 2016. Of the seven regions that we track in the U.S., Seattle is the only region that experienced an increase in the number of Series A raises in 2016, at 4%.

While overall Series A activity declined slightly in Los Angeles, there were two large Series A raises for female-led businesses — (i) HopSkipDrive, led by CEO Joanna McFarland, which raised $10.2 million in January 2016 from Upfront Ventures and FirstMark Capital; and (ii) Hutch, led by CEO Beatrice Fischel-Bock, which raised $5 million in July 2016 from Founders Fund. Los Angeles remains among the most female entrepreneur-friendly cities in the U.S.

 

VC’s investing in female-led companies in 2016.

Female Founders Fund remained the most active investor, participating in 3 of the 14 — or 21% — of all female-led A rounds in NYC. – See more at: http://femalefoundersfund.com/2016-review-of-female-founders-raising-institutional-capital/#sthash.Pcuj7rVB.dpuf

– See more at:

http://femalefoundersfund.com/2016-review-of-female-founders-raising-institutional-capital/#sthash.Pcuj7rVB.dpuf

Read Full Post »

On Investment Platforms for Private Funds and Investment Platforms for Private Placements – SEC Update

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Health Law & Patient Safety, Intellectual Property, Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough, Patent Law in Biotech, Venture Capital, tagged on February 1, 2017| Leave a Comment »

On Investment Platforms for Private Funds and Investment Platforms for Private Placements – SEC Update

Reporter: Aviva Lev-Ari, PhD, RN

 

SEC Update

December 2015

Finders and Unregistered Broker-Dealers

In the last few years, we have seen a number of important developments in the securities laws related to finders and broker-dealer registration requirements. Below we provide an overview of the broker-dealer registration requirement as it relates to finders who assist in matching issuers with investors or buyers and the latest developments in this area.

Overview

The distinction between being classified as a finder and a broker-dealer can have significant consequences. An unregistered broker-dealer may face sanctions from the Securities and Exchange Commission (SEC), and it may be unable to enforce payment for its services. In addition, transactions involving an unregistered broker-dealer may create a right of rescission in favor of the investors, allowing the investors the right to require the issuer to return the money invested. One example of the consequences of an unregistered broker-dealer occurred in the Ranieri Partners SEC enforcement action. In that action the SEC brought charges against a private-equity firm, its managing director, and a consultant because of the consultant’s failure to register as a broker-dealer. The SEC’s order found that the private equity firm paid transaction-based fees to a consultant, who was not registered as a broker-dealer, for soliciting investors for private fund investments.1

The federal securities laws do not specifically define the term “finder” or outline what finders can do. Instead, finders must avoid being deemed a broker or dealer under the federal securities laws unless they register as such with the SEC and the Financial Industry Regulatory Authority (FINRA). A broker is defined as “any person engaged in the business of effecting transactions in securities for the accounts of others.”2 A dealer is defined as a person that is “engaged in the business of buying and selling securities … for such person’s own account,” but excludes a person that buys and sells securities for its own account, but not as part of a regular business.3Because the broker definition is the one that finders have the most trouble with, this discussion is focused on what activities may cause a finder to fall within the definition of a broker required to register with the SEC and FINRA.

  • M&A Brokers
  • FINRA Guidance
  • Investment Platforms for Private Placements
  • Investment Platforms for Private Funds
  • Crowdfunding
  • Potential Regulatory Action
Conclusion

A determination of whether an intermediary is acting as a finder or an unregistered broker-dealer is a very fact-specific analysis and can often be very complex. Unfortunately for unwary entrepreneurs, company executives, and equity fund sponsors, frequently a third party assisting with capital-raising will be acting as a broker-dealer, not a finder, and therefore should not be engaged unless properly registered. It is likely that we will see further clarification or new rules from regulators in the future; regardless, it is important to always carefully consider the involvement of finders or broker-dealers in any capital-raising endeavor.

If you have any questions regarding the use of finders, or capital raising in general, please contact the Venable lawyer with whom you work, one of the authors of this article, or a member of our Corporate Finance and Securities Group.

SOURCE
https://www.venable.com/finders-and-unregistered-broker-dealers-12-04-2015/?utm_source=Mondaq&utm_medium=syndication&utm_campaign=View-Original

Read Full Post »

Funding Oncorus’s Immunotherapy Platform: Next-generation Oncolytic Herpes Simplex Virus (oHSV) for Brain Cancer, Glioblastoma Multiforme (GBM)

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Oncolytic virus & OncoViro-Therapy on December 28, 2016| Leave a Comment »

Funding Oncorus’s Immunotherapy Platform: Next-generation Oncolytic Herpes Simplex Virus (oHSV) for Brain Cancer, Glioblastoma Multiforme (GBM)

Reporter: Aviva Lev-Ari, PhD, RN

 

Series A  Funding in July 2016 and in December 2016

Jul 20, 2016 at 2:19 PM

  • raised $57M to battle cancer —

SOURCE

http://medcitynews.com/2016/07/qa-ceo-oncorus-just-raised-57m-battle-cancer/?rf=1

 

MPM Capital

MPM Capital, which has around $2 billion in assets, is already working with drugmakers on funding healthcare startups. This  includes a venture fund it closed last year at $400 million that included Novartis ($NVS) Astellas Pharma as investors.

http://www.fiercebiotech.com/biotech/ubs-raises-471m-for-a-new-kind-cancer-research-fund

(with equal contributions from MPM BV2014 and the Oncology Impact Fund), and included Deerfield Management, Arkin Bio Ventures, Celgene, Inc., Excelyrate Capital, Long March Investment Fund and MPM’s SunStates Fund.

  1. MPM BV2014  – OIF will co-invest with MPM’s BV2014 venture fund in private oncology company investments.

http://finance.yahoo.com/news/mpm-launches-471-million-social-194500117.html

  1. MPM Oncology Impact Fund (OIF)

https://www.ft.com/content/b5e1e678-0c6a-11e6-b0f1-61f222853ff3

 

 

COINVESTORS:

 

SOURCE

http://medcitynews.com/2016/07/qa-ceo-oncorus-just-raised-57m-battle-cancer/?rf=1

http://www.finsmes.com/2016/07/immuno-oncology-company-oncorus-completes-57m-series-a-financing.html

 

December 15, 2016

 

Oncorus®, Inc. Announces Additional Series A Financing Support From Astellas Venture Management LLC (AVM)

  • AVM (61-57 = $4Million) – Now all proceeds are $61Million

 

Oncorus Management – “We are thrilled to have AVM join this outstanding group of high-quality investors.

http://www.oncorus.com/board-of-directors

 

  • Industry veteran and Oncorus co-founder Mitchell H. Finer, Ph.D., leads the Oncorus management team as Chief Executive Officer and Chief Scientific Officer and
  • Cyrus D. Mozayeni, M.D., serves as President and Chief Business Officer.

 

Finer serves on Oncorus’s Board of Directors along with:
– Luke Evnin, Ph.D., MPM Capital co-founder and Chairman,
– Briggs Morrison, CEO, Syndax;
– Cameron Wheeler, Ph.D., Principal, Deerfield Management; and,
– Alon Lazarus, Ph.D., Biotech Investment Manager, Arkin Bio Ventures.

This additional funding will help advance our immunotherapy platform as we discover innovative new therapies which we hope will be of benefit to patients in need and the physicians who treat them,” said Dr. Finer.

 

Oncorus licensed certain patent rights from the University of Pittsburgh based upon the work of renowned scientists Joseph Glorioso III, Ph.D., and Paola Grandi, Ph.D., who will join Oncorus’s Scientific Advisory Board.

The company will invest in researching and developing oncolytic viral constructs which will move through preclinical development and ultimately into clinical trials. Currently, the company’s lead candidate is in preclinical development for GBM. The company will also expand and improve its technology platform and accelerate the development of pipeline programs in other forms of cancer.

 

About AVM Astellas Venture Management LLC., based in Menlo Park, California, is a corporate venture capital of Astellas Pharma Inc. (“API”), headquartered in Tokyo, Japan. For over 15 years, AVM has been making strategic investments to achieve its mission to explore emerging innovative companies, which have potential to become API’s collaboration partners in R&D. For more information, please visit the website at www.astellasventure.com.

About Oncorus, Inc. Oncorus, Inc. is an early-stage biotechnology company developing a next-generation immunotherapy platform of oncolytic viruses to treat several types of cancer, including highly malignant and aggressive cancers. A leader in corporate philanthropy, Oncorus has taken a pledge to donate a portion of product sales revenue to fund promising cancer research and to support cancer care in the developing world. The company is located in Kendall Square, Cambridge, Massachusetts. Visit www.oncorus.com, for more information.

 

SOURCE

https://static1.squarespace.com/static/574456597c65e4f329ea6950/t/5852b919d1758eb23d44fdd1/1481816345729/Oncorus+Series+A+Astellas+Press+Release+FINAL+12-15-16.pdf

http://www.oncorus.com/news-items/2016/12/15/oncorus-inc-announces-additional-series-a-financing-support-from-astellas-venture-management-llc

Read Full Post »

Runway: a unique startup incubator in NYC – JACOBS TECHNION-CORNELL INSTITUTE @CORNELL TECH

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Foundations for supporting Science and Education, Scientist: Career considerations on October 24, 2016| Leave a Comment »

Runway: a unique startup incubator in NYC – JACOBS TECHNION-CORNELL INSTITUTE  @CORNELL TECH

 

Jacobs Technion-Cornell Institute

campus-view-from-manhattan-aerial

 

Author: Shuli (Shoulamit) C. Shwartz, PhD

Entrepreneur in Residence, CornellTech, NYC

Co-managing Runway Startup Postdoc  program

Jacobs Technion-Cornell Institute

 

The Runway  is a 1-3 years tech incubator in the Jacobs Technion-Cornell Institute at CornellTech. It is an innovative hybrid of a postdoc educational program and a startup incubator, highly competitive, providing PhD graduates with a supportive environment that includes

  • funding,
  • high level mentoring in technology,
  • business and entrepreneurship,
  • space and more. 

Application is now open for 2017 Fall’s cohort. 

More details are available here.

 

Shuli (Shoulamit) C. Shwartz, PhD

Entrepreneur in Residence, CornellTech, NYC

Co-managing Runway Startup Postdoc  program

Jacobs Technion-Cornell Institute

Read Full Post »

Real Time Coverage and eProceedings of Presentations on 9/19-9/21 @CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media, CRISPR/Cas9 & Gene Editing, Drug Delivery Platform Technology, Drug Development Process, Drug Toxicity, FDA, Genetics & Innovations in Treatment, Genetics & Pharmaceutical, Genome Biology, Genomic Testing: Methodology for Diagnosis, Global Partnering & Biotech Investment on September 25, 2016| Leave a Comment »

Real Time Coverage and eProceedings of Presentations on 9/19-9/21 @CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

Curator: Aviva Lev-Ari, PhD, RN

2.1.5.11

2.1.5.11   Real Time Coverage and eProceedings of Presentations on 9/19-9/21 @CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

LIVE 9/19 8AM – 10AM USING CRISPR/Cas9 FOR FUNCTIONAL SCREENING at CHI’s 2nd Annual Symposium CRISPR: Mechanisms and Applications @CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/09/19/live-919-8am-10am-using-crisprcas9-for-functional-screening-at-chis-2nd-annual-symposium-crispr-mechanisms-and-applications-chis-14th-discovery-on-target-919-9222/

LIVE 9/19 9:40 – noon CRISPR Engineering Lymphoma Lines & Will Interference from CRISPR Silence RNAi? CHI’s 2nd Annual Symposium CRISPR: Mechanisms and Applications @ CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/09/19/live-919-940-noon-crispr-engineering-lymphoma-lines-will-interference-from-crispr-silence-rnai-chis-2nd-annual-symposium-crispr-mechanisms-and-applications-chis-14th/

LIVE 9/19 1:40 – 3:20 EMERGING APPLICATIONS OF CRISPR/CAS9 at CHI’s 2nd Annual Symposium CRISPR: Mechanisms and Applications @ CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/09/19/live-919-140-320-emerging-applications-of-crisprcas9-at-chis-2nd-annual-symposium-crispr-mechanisms-and-applications-chis-14th-discovery-on-target-919-9222016/

LIVE 9/19 4PM – 5:30PM NK CELL-BASED CANCER IMMUNOTHERAPY @CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/09/19/live-919-4pm-530pm-nk-cell-based-cancer-immunotherapy-chis-14th-discovery-on-target-919-9222016-westin-boston-waterfront-boston/

LIVE 9/20 8AM to noon GENE THERAPIES BREAKTHROUGHS at CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/09/20/live-920-8am-to-noon-gene-therapies-breakthroughs-at-chis-14th-discovery-on-target-919-9222016-westin-boston-waterfront-boston/

LIVE 9/20 2PM to 5:30PM New Viruses for Therapeutic Gene Delivery at CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/09/20/live-920-2pm-to-530pm-new-viruses-for-therapeutic-gene-delivery-at-chis-14th-discovery-on-target-919-9222016-westin-boston-waterfront-boston/

LIVE 9/21 8AM to 10:55 AM Expoloring the Versatility of CRISPR/Cas9 at CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/09/21/live-921-8am-to-1055-am-expoloring-the-versatility-of-crisprcas9-at-chis-14th-discovery-on-target-919-9222016-westin-boston-waterfront-boston/

LIVE 9/21 8AM to 2:40PM Targeting Cardio-Metabolic Diseases: A focus on Liver Fibrosis and NASH Targets at CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/09/21/live-921-8am-to-240pm-targeting-cardio-metabolic-diseases-a-focus-on-liver-fibrosis-and-nash-targets-at-chis-14th-discovery-on-target-919-9222016-westin-boston-waterfront-b/

LIVE 9/21 12:50 pm Plenary Keynote Program at CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/09/21/live-921-1250-pm-plenary-keynote-program-at-chis-14th-discovery-on-target-919-9222016-westin-boston-waterfront-boston/

LIVE 9/21 3:20PM to 6:40PM KINASE INHIBITORS FOR CANCER IMMUNOTHERAPY COMBINATIONS & KINASE INHIBITORS FOR AUTOIMMUNE AND INFLAMMATORY DISEASES at CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/09/21/live-921-320pm-to-640pm-kinase-inhibitors-for-cancer-immunotherapy-combinations-kinase-inhibitors-for-autoimmune-and-inflammatory-diseases-at-chis-14th-discovery-on-target-919/

Read Full Post »

« Newer Posts - Older Posts »